Back to All

Diaceutics receives nomination for International Star in the European Small and Mid-Cap Awards 2020

3 July, 2020

Diaceutics PLC received confirmation this week that the company has been nominated in the International Star category in the European Small and Mid-Cap Awards, due to take place in Berlin in November 2020. 

The awards are a joint initiative by EuropeanIssuers, FESE and the European Commission to showcase SMEs that recently went through an IPO.

In the announcement Florence Bindelle, Secretary General of European Issuers, said:

“Supporting small and medium enterprises (SMEs) and equity financing are essential to fuel Europe’s economy. This acquires even greater importance in light of the current crisis triggered by the COVID-19 outbreak. To build stronger European equity capital markets we need to endorse SMEs in accessing finance through public markets and improve the IPO ecosystem.”

The official press release announcing the awards stated that:

Small and Mid-Cap companies are vitally important in supporting the European economy and further added

…Our Awards this year are even more significant as it is exactly these types of companies that will be key to re-equitising the European economy, we therefore need to recognise and congratulate them on their successes to date. 

The objective of the Awards is to showcase the best European Small and mid-sized companies that have gained access to capital markets via an IPO and who the organisers state are “critical to accomplishing the EU’s goals of job creation, competitiveness and growth.”

The announcement of the nominees was made this week and the winners will be chosen and announced in November 2020.

Full details on other nominees and organiser comments can be found in the official press release for announcement here. http://www.europeanissuers.eu/docs/view/5ef9fefb0546e-en 

About Diaceutics

At Diaceutics we believe that every patient should get the precision medicine they deserve. We are a data analytics and end-to-end services provider enabled by DXRX - the world’s first Network solution for the development and commercialization of precision medicine diagnostics. 

Diaceutics has worked on every precision medicine brought to market and provides services to 36 of the world’s leading pharmaceutical companies. We have built the world’s largest repository of diagnostic testing data with a growing network of 2500 labs in 51 countries.